Inhalable Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Inhalable Drug Delivery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.

The report provides comprehensive information about the Inhalable Drug Delivery pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

An Inhalable Drug Delivery device is meant to administer medications that are to be inhaled deeply into the lungs. Drugs are delivered either by the nasal or oral respiratory route.

Scope

• Extensive coverage of the Inhalable Drug Delivery under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Inhalable Drug Delivery and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to:

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Inhalable Drug Delivery under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product’s current stage of development, territory and estimated launch date

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Inhalable Drug Delivery Overview

3 Products under Development

4 Inhalable Drug Delivery – Pipeline Products under Development by Companies

5 Inhalable Drug Delivery Companies and Product Overview

6 Inhalable Drug Delivery- Recent Developments

7 Appendix

Companies Mentioned

• Acerus Pharmaceuticals Corp
• Acorda Therapeutics Inc
• Actervis GmbH
• Aerami Therapeutics Inc
• Aerophase Inc
• Alexza Pharmaceuticals Inc
• Baxter International Inc
• Bellerophon Therapeutics Inc
• Breath Therapeutics Holding BV
• California Northstate University College of Medicine
• Canigma A.L LTD
• Cipla Ltd
• Department of Biomedical Engineering Columbia University
• Edixomed Ltd
• Engage Therapeutics Inc
• iDTx Systems, Inc.
• Impel Pharmaceuticals Inc
• Inhalation Sciences Sweden AB
• Invero Pharma LLC
• Jupiter Research LLC
• Kanabo Research Ltd
• Lupin Pharmaceuticals Inc
• Mallinckrodt Plc
• Medical Developments International Ltd
• Medspray BV
• Monash University
• Nemera La Verpilliere
• Next Safety, Inc.
• Nobilis Therapeutics Inc
• OncoSec Medical Inc
• Pharmosa Biopharm Inc
• Rhinomed Ltd
• Risproly
• Rutgers Cancer Institute of New Jersey
• Sandoz International GmbH
• Seng Vital International GmbH
• Shenzhen Smoore Technology Ltd
• Sino Biopharmaceutical Ltd
• Technology Commercialization Partners LLC
• Tetra Bio-Pharma Inc
• Teva Pharmaceutical Industries Ltd
• Texas Tech University Health Sciences Center
• Third Pole Inc
• Tiziana Life Sciences PLC
• Torrent Pharmaceuticals Ltd
• University Hospital Southampton NHS Foundation Trust
• University of Texas Health Science Center at Houston
• Vectura Group Plc
• Veoli Ltd
• Vero Biotech LLC
• Via Therapeutics LLC
• Virpax Pharmaceuticals Inc
• VistaGen Therapeutics Inc
• VitalMIST
• Wellfully Ltd
• Windtree Therapeutics Inc

For more information about this report visit https://www.researchandmarkets.com/r/27o1l4

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900